Tests CAR-T cell therapy in people with HIV whose virus is suppressed
Tests CAR-T cell therapy in adults with HIV whose virus is suppressed by treatment.
Plain-language title generated from the registry record
Registry title: The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults living with HIV whose virus is well controlled by antiretroviral treatment (cART). It tests CAR-T cell therapy.
- Age
- 18 to 60 years
- Sex
- All sexes can join.
- Disease stage
- HIV infection confirmed, with virus in the blood below 50 copies/ml and CD4 cell count above 350 cells/ul.
- Earlier treatment
- Must have been on cART for more than 12 months.
- Biomarker or test result
- HIV viral load below 50 copies/ml; CD4 cell count above 350 cells/ul.
Main reasons for not taking part
- Active hepatitis B or hepatitis C infection, or serious opportunistic infections
- Serious chronic disease such as diabetes or mental illness
- Serious liver, heart or kidney disease
- History of pancreatitis during cART
- Pregnant or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT03240328, who can take part
Where in China
- Guangzhou 8th People's HospitalGuangzhou, ChinaContact: Linghua LI, doctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Guangzhou 8th People's Hospital
- Trial code
- NCT03240328
- Record updated
- 14 September 2022
- Original description
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.Read full original descriptionShow less
The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
Inclusion: HIV infection confirmed; Receiving cART more than 12 months; HIV viral-load < 50 copies/ml and CD4 cell count more than 350 cells/ul; Without serious liver, heart, liver and kidney diseases; The subjects know about the study and volunteer to attend the research and sign the informed consent.
Exclusion: With active HBV or HCV infection, or serious opportunistic infections; With serious chronic disease such like diabetes, the mental illness,et al; History of suffering from pancreatitis during cART; Pregnant or breast-fed; With poor adherence; Unable to complete follow up.